Abstract

The complex between the proteins MDM2 and p53 is a promising drug target for cancer therapy. The residues 19–26 of p53 have been biochemically and structurally demonstrated to be a most critical region to maintain the association of MDM2 and p53. Variation of the amino acid sequence in this range obviously alters the binding affinity. Surprisingly, suitable substitutions contiguous to this region of the p53 peptides can yield tightly binding peptides. The peptide variants may differ by a single residue that vary little in their structural conformations and yet are characterized by large differences in their binding affinities. In this study a systematic analysis into the role of single C-terminal mutations of a 12 residue fragment of the p53 transactivation domain (TD) and an equivalent phage optimized peptide (12/1) were undertaken to elucidate their mechanistic and thermodynamic differences in interacting with the N-terminal of MDM2. The experimental results together with atomistically detailed dynamics simulations provide insight into the principles that govern peptide design protocols with regard to protein-protein interactions and peptidomimetic design.

Highlights

  • The tumour suppressor protein p53 is a transcription factor that plays an essential role in guarding the cell in response to a variety of stress signals through induction of cell cycle arrest, apoptosis or senescence [1,2]

  • Recent papers have reported the discovery and development of peptides with nanomolar affinities that interact with MDM2 and bind tightly to MDM4

  • Our studies have focused on the mechanism by which these peptides interact with MDM2 and how these peptides can be converted from the low micromolar and high nanomolar binding affinities to much more potent binding entities

Read more

Summary

Introduction

The tumour suppressor protein p53 is a transcription factor that plays an essential role in guarding the cell in response to a variety of stress signals through induction of cell cycle arrest, apoptosis or senescence [1,2]. MDM2 is overexpressed in many cancers, and is thought to be one of the primary causes of the inactivation of the p53 network in p53 wild type tumours [1]. In such cases, disruption of the MDM2:p53 interaction has been shown to stabilize and activate the transcriptional activity of p53 leading to cell death or to G1/G2 cell cycle arrest [5,6]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.